Cargando…
Early Adoption of Dabigatran and Its Dosing in US Patients With Atrial Fibrillation: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation
BACKGROUND: Dabigatran is a novel oral anticoagulant approved for thromboprophylaxis in atrial fibrillation. Adoption patterns of this new agent in community practice are unknown. METHODS AND RESULTS: We studied patterns of dabigatran use among patients enrolled in the Outcomes Registry for Better I...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3886732/ https://www.ncbi.nlm.nih.gov/pubmed/24275632 http://dx.doi.org/10.1161/JAHA.113.000535 |
_version_ | 1782478912210599936 |
---|---|
author | Steinberg, Benjamin A. Holmes, DaJuanicia N. Piccini, Jonathan P. Ansell, Jack Chang, Paul Fonarow, Gregg C. Gersh, Bernard Mahaffey, Kenneth W. Kowey, Peter R. Ezekowitz, Michael D. Singer, Daniel E. Thomas, Laine Peterson, Eric D. Hylek, Elaine M. |
author_facet | Steinberg, Benjamin A. Holmes, DaJuanicia N. Piccini, Jonathan P. Ansell, Jack Chang, Paul Fonarow, Gregg C. Gersh, Bernard Mahaffey, Kenneth W. Kowey, Peter R. Ezekowitz, Michael D. Singer, Daniel E. Thomas, Laine Peterson, Eric D. Hylek, Elaine M. |
author_sort | Steinberg, Benjamin A. |
collection | PubMed |
description | BACKGROUND: Dabigatran is a novel oral anticoagulant approved for thromboprophylaxis in atrial fibrillation. Adoption patterns of this new agent in community practice are unknown. METHODS AND RESULTS: We studied patterns of dabigatran use among patients enrolled in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT‐AF) Registry between June 2010 and August 2011 and followed for 12 months. Among 9974 atrial fibrillation patients included, 1217 (12%) were treated with dabigatran during the study. Overall, patients receiving dabigatran were younger (median age 72 versus 75 years, P<0.0001), more likely to be white (92% versus 89%, P=0.005), more likely to have private insurance (33% versus 25%, P<0.0001), and less likely to have prior cardiovascular disease (4% versus 33%, P<0.0001). They had more new‐onset atrial fibrillation (8.8% versus 4.1%, P<0.0001), lower CHADS(2) scores (estimated risk based on the presence of congestive heart failure, hypertension, aged ≥75 years, diabetes mellitus, and prior stroke or transient ischemic attack; mean 2.0 versus 2.3, P<0.0001), and lower Anticoagulation and Risk Factors in Atrial Fibrillation scores (mean 2.4 versus 2.8, P<0.0001). More than half (n=14/25, 56%) of patients with severe kidney disease were not prescribed reduced dosing, whereas 10% (n=91/920) with preserved renal function received lower dosing. Among patients not on dabigatran at baseline, 8% had dabigatran initiated during follow‐up. Patient education was significantly associated with switching from warfarin to dabigatran (adjusted odds ratio for postgraduate 1.73, P=0.007), whereas antiarrhythmic drug use significantly correlated with de novo adoption of dabigatran (adjusted odds ratio 2.4, P<0.0001). CONCLUSIONS: Patients receiving dabigatran were younger and at a lower risk of stroke and bleeding. Patients appeared to drive switching from warfarin, whereas clinical characteristics influenced de novo start of dabigatran. These data suggest cautious early uptake of dabigatran, and more careful attention to dosing adjustments is warranted. CLINICAL TRIAL REGISTRATION: URL: Clinicaltrials.gov. Unique identifier: NCT01165710. |
format | Online Article Text |
id | pubmed-3886732 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Blackwell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-38867322014-01-10 Early Adoption of Dabigatran and Its Dosing in US Patients With Atrial Fibrillation: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation Steinberg, Benjamin A. Holmes, DaJuanicia N. Piccini, Jonathan P. Ansell, Jack Chang, Paul Fonarow, Gregg C. Gersh, Bernard Mahaffey, Kenneth W. Kowey, Peter R. Ezekowitz, Michael D. Singer, Daniel E. Thomas, Laine Peterson, Eric D. Hylek, Elaine M. J Am Heart Assoc Original Research BACKGROUND: Dabigatran is a novel oral anticoagulant approved for thromboprophylaxis in atrial fibrillation. Adoption patterns of this new agent in community practice are unknown. METHODS AND RESULTS: We studied patterns of dabigatran use among patients enrolled in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT‐AF) Registry between June 2010 and August 2011 and followed for 12 months. Among 9974 atrial fibrillation patients included, 1217 (12%) were treated with dabigatran during the study. Overall, patients receiving dabigatran were younger (median age 72 versus 75 years, P<0.0001), more likely to be white (92% versus 89%, P=0.005), more likely to have private insurance (33% versus 25%, P<0.0001), and less likely to have prior cardiovascular disease (4% versus 33%, P<0.0001). They had more new‐onset atrial fibrillation (8.8% versus 4.1%, P<0.0001), lower CHADS(2) scores (estimated risk based on the presence of congestive heart failure, hypertension, aged ≥75 years, diabetes mellitus, and prior stroke or transient ischemic attack; mean 2.0 versus 2.3, P<0.0001), and lower Anticoagulation and Risk Factors in Atrial Fibrillation scores (mean 2.4 versus 2.8, P<0.0001). More than half (n=14/25, 56%) of patients with severe kidney disease were not prescribed reduced dosing, whereas 10% (n=91/920) with preserved renal function received lower dosing. Among patients not on dabigatran at baseline, 8% had dabigatran initiated during follow‐up. Patient education was significantly associated with switching from warfarin to dabigatran (adjusted odds ratio for postgraduate 1.73, P=0.007), whereas antiarrhythmic drug use significantly correlated with de novo adoption of dabigatran (adjusted odds ratio 2.4, P<0.0001). CONCLUSIONS: Patients receiving dabigatran were younger and at a lower risk of stroke and bleeding. Patients appeared to drive switching from warfarin, whereas clinical characteristics influenced de novo start of dabigatran. These data suggest cautious early uptake of dabigatran, and more careful attention to dosing adjustments is warranted. CLINICAL TRIAL REGISTRATION: URL: Clinicaltrials.gov. Unique identifier: NCT01165710. Blackwell Publishing Ltd 2013-12-19 /pmc/articles/PMC3886732/ /pubmed/24275632 http://dx.doi.org/10.1161/JAHA.113.000535 Text en © 2013 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/3.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Research Steinberg, Benjamin A. Holmes, DaJuanicia N. Piccini, Jonathan P. Ansell, Jack Chang, Paul Fonarow, Gregg C. Gersh, Bernard Mahaffey, Kenneth W. Kowey, Peter R. Ezekowitz, Michael D. Singer, Daniel E. Thomas, Laine Peterson, Eric D. Hylek, Elaine M. Early Adoption of Dabigatran and Its Dosing in US Patients With Atrial Fibrillation: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation |
title | Early Adoption of Dabigatran and Its Dosing in US Patients With Atrial Fibrillation: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation |
title_full | Early Adoption of Dabigatran and Its Dosing in US Patients With Atrial Fibrillation: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation |
title_fullStr | Early Adoption of Dabigatran and Its Dosing in US Patients With Atrial Fibrillation: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation |
title_full_unstemmed | Early Adoption of Dabigatran and Its Dosing in US Patients With Atrial Fibrillation: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation |
title_short | Early Adoption of Dabigatran and Its Dosing in US Patients With Atrial Fibrillation: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation |
title_sort | early adoption of dabigatran and its dosing in us patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3886732/ https://www.ncbi.nlm.nih.gov/pubmed/24275632 http://dx.doi.org/10.1161/JAHA.113.000535 |
work_keys_str_mv | AT steinbergbenjamina earlyadoptionofdabigatrananditsdosinginuspatientswithatrialfibrillationresultsfromtheoutcomesregistryforbetterinformedtreatmentofatrialfibrillation AT holmesdajuanician earlyadoptionofdabigatrananditsdosinginuspatientswithatrialfibrillationresultsfromtheoutcomesregistryforbetterinformedtreatmentofatrialfibrillation AT piccinijonathanp earlyadoptionofdabigatrananditsdosinginuspatientswithatrialfibrillationresultsfromtheoutcomesregistryforbetterinformedtreatmentofatrialfibrillation AT anselljack earlyadoptionofdabigatrananditsdosinginuspatientswithatrialfibrillationresultsfromtheoutcomesregistryforbetterinformedtreatmentofatrialfibrillation AT changpaul earlyadoptionofdabigatrananditsdosinginuspatientswithatrialfibrillationresultsfromtheoutcomesregistryforbetterinformedtreatmentofatrialfibrillation AT fonarowgreggc earlyadoptionofdabigatrananditsdosinginuspatientswithatrialfibrillationresultsfromtheoutcomesregistryforbetterinformedtreatmentofatrialfibrillation AT gershbernard earlyadoptionofdabigatrananditsdosinginuspatientswithatrialfibrillationresultsfromtheoutcomesregistryforbetterinformedtreatmentofatrialfibrillation AT mahaffeykennethw earlyadoptionofdabigatrananditsdosinginuspatientswithatrialfibrillationresultsfromtheoutcomesregistryforbetterinformedtreatmentofatrialfibrillation AT koweypeterr earlyadoptionofdabigatrananditsdosinginuspatientswithatrialfibrillationresultsfromtheoutcomesregistryforbetterinformedtreatmentofatrialfibrillation AT ezekowitzmichaeld earlyadoptionofdabigatrananditsdosinginuspatientswithatrialfibrillationresultsfromtheoutcomesregistryforbetterinformedtreatmentofatrialfibrillation AT singerdaniele earlyadoptionofdabigatrananditsdosinginuspatientswithatrialfibrillationresultsfromtheoutcomesregistryforbetterinformedtreatmentofatrialfibrillation AT thomaslaine earlyadoptionofdabigatrananditsdosinginuspatientswithatrialfibrillationresultsfromtheoutcomesregistryforbetterinformedtreatmentofatrialfibrillation AT petersonericd earlyadoptionofdabigatrananditsdosinginuspatientswithatrialfibrillationresultsfromtheoutcomesregistryforbetterinformedtreatmentofatrialfibrillation AT hylekelainem earlyadoptionofdabigatrananditsdosinginuspatientswithatrialfibrillationresultsfromtheoutcomesregistryforbetterinformedtreatmentofatrialfibrillation AT earlyadoptionofdabigatrananditsdosinginuspatientswithatrialfibrillationresultsfromtheoutcomesregistryforbetterinformedtreatmentofatrialfibrillation |